ACTION: Myriad Genetics, Inc. (“MYGN”) has announced a distribution of Myriad Pharmaceuticals Inc. (“MYRXV”) Common Shares. The distribution ratio is .25 MYRXV Common Shares per MYGN Common Share. The record date is June 17, 2009; the mail date is June 30, 2009. The NASDAQ NMS has set June 15, 2009 as the ex-distribution of the distribution.
Myriad Pharmaceuticals Inc. is currently trading “when issued” on NASDAQ under the symbol “MYRXV”.
This action will be coordinated with the Options Clearing Corporation.
CATEGORY: Stock Distribution
EQUITY SYMBOL: Myriad Genetics, Inc. (“MYGN”)
ONE CHICAGO SYMBOL: MYGN1C will change to MYGN2C
CME FUTURES SYMBOL: MYG for the re-listed MYGN1C; MY8 for the MYGN2C
MULTIPLIER: 100 (e.g., 1.00 equals $100.00)
EFFECTIVE DATE: Tuesday, June 16, 2009
NEW DELIVERABLE PER CONTRACT: For the MYGN2C:
1) 100 Myriad Genetics, Inc. (“MYGN”) Common Shares
2) 25 Myriad Pharmaceuticals Inc. (“MYRXV”) Common Shares
For the re-listed MYGN1C:
100 Myriad Genetics, Inc. (“MYGN”) common shares.
APPLICABLE CONTRACT MONTHS: June, July, September, December 2009
SETTLEMENT PRICES AND POSITIONS: The underlying price for the MYGN2C Futures contract deliverable, expressed in term of current market value, would be calculated as follows:
MYGN2C = MYG + 25 (MYRXV)
Please note that the valuation would apply only to the MYGN2C deliverable in terms of current market value of the deliverable securities. The resulting price would not be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends, and other factors.
NOTES: The forecasted effect of the upcoming corporate event on each clearing firms’ positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report (ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).
If you have any questions regarding the information provided in the document, please call CME Clearing risk management hotline at (312) 648-3888.